NCT05730894

Brief Summary

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) support is a lifesaving tool used to treat cardiogenic shock, acute heart failure, or extracorporeal cardiopulmonary resuscitation(CPR). However, its use is associated with significant complications, including mortality. We aim to conduct a retrospective observational study of all patients at Heart Hospital who required VA-ECMO support due to cardiogenic shock during 1/06/2016 and 1/06/2022 to report the incidence of in-hospital mortality among patients who required VA-ECMO along with the predictors of mortality. Data will be collected to identify baseline characteristics and outcomes including clinical variables predictive of poor outcomes.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 5, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 16, 2023

Completed
12 days until next milestone

Study Start

First participant enrolled

February 28, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2023

Completed
Last Updated

February 16, 2023

Status Verified

November 1, 2022

Enrollment Period

3 months

First QC Date

December 5, 2022

Last Update Submit

February 15, 2023

Conditions

MoralityVA-ECMO

Keywords

mortalityVA-ECMOoutcome

Outcome Measures

Primary Outcomes (1)

  • mortality

    mortality in patients who had VA-ECMO

    6 months

Secondary Outcomes (1)

  • bacterial pathogens responsible for infection-related mortality in VA-ECMO

    1 month

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Requirement of VA-ECMO support

You may qualify if:

  • Adults with the age of ≥ 18 years
  • Requiring VA-ECMO or VAV-ECMO support

You may not qualify if:

  • Requiring VV-ECMO support

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hamad medical corporation

Doha, DA, 3050, Qatar

RECRUITING

Central Study Contacts

Alaa Rahhal, Msc

CONTACT

44395646ARahhal1@hamad.qa

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2022

First Posted

February 16, 2023

Study Start

February 28, 2023

Primary Completion

June 1, 2023

Study Completion

July 1, 2023

Last Updated

February 16, 2023

Record last verified: 2022-11

Locations

QA(1)